The estimated Net Worth of Lewis H Jr Titterton is at least $3.56 millió dollars as of 30 July 2024. Mr. Titterton owns over 27,226 units of Anixa Biosciences stock worth over $2,769,672 and over the last 9 years he sold ANIX stock worth over $651,000. In addition, he makes $136,575 as Lead Independent Director at Anixa Biosciences.
Sign up
Mr. Titterton ANIX stock SEC Form 4 insiders trading
Lewis has made over 41 trades of the Anixa Biosciences stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 27,226 units of ANIX stock worth $84,128 on 30 July 2024.
The largest trade he's ever made was selling 210,000 units of Anixa Biosciences stock on 24 August 2016 worth over $651,000. On average, Lewis trades about 15,320 units every 57 days since 2015. As of 30 July 2024 he still owns at least 896,334 units of Anixa Biosciences stock.
You can see the complete history of Mr. Titterton stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Lewis Titterton biography
Lewis H. Titterton Jr. serves as Lead Independent Director of the Company. His background is in high technology with an emphasis on health care and he was the Chairman of the Board of Directors of NYMED, Inc., a diversified health services company, from 1989 until October 2018. Mr. Titterton founded MedE America, Inc. in 1986 and was Chief Executive Officer of Management and Planning Services, Inc. from 1978 to 1986. Mr. Titterton also served as one of our Directors from July 1999 to January 2003. He holds an MBA from the State University of New York at Albany, and a B.A. degree from Cornell University. Mr. Titterton has been involved with our Company as a director or investor for over twenty years. Mr. Titterton also has substantial experience with advising on the strategic development of technology companies and over forty years of experience in various aspects of the technology industry.
What is the salary of Lewis Titterton?
As the Lead Independent Director of Anixa Biosciences, the total compensation of Lewis Titterton at Anixa Biosciences is $136,575. There are 5 executives at Anixa Biosciences getting paid more, with Dr. Amit Kumar Ph.D. having the highest compensation of $720,865.
How old is Lewis Titterton?
Lewis Titterton is 75, he's been the Lead Independent Director of Anixa Biosciences since 2018. There are no older and 10 younger executives at Anixa Biosciences.
What's Lewis Titterton's mailing address?
Lewis's mailing address filed with the SEC is C/O ANIXA BIOSCIENCES, INC., 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE,, CA, 95118.
Insiders trading at Anixa Biosciences
Over the last 6 years, insiders at Anixa Biosciences have traded over $0 worth of Anixa Biosciences stock and bought 834,156 units worth $2,822,805 . The most active insiders traders include Amit Kumar, Lewis H Jr Titterton és Arnold M Baskies. On average, Anixa Biosciences executives and independent directors trade stock every 31 days with the average trade being worth of $78,894. The most recent stock trade was executed by Lewis H Jr Titterton on 30 July 2024, trading 27,226 units of ANIX stock currently worth $84,128.
What does Anixa Biosciences do?
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
What does Anixa Biosciences's logo look like?
Complete history of Mr. Titterton stock trades at ParkerVision és Anixa Biosciences
Anixa Biosciences executives and stock owners
Anixa Biosciences executives and other stock owners filed with the SEC include:
-
Dr. Amit Kumar Ph.D.,
Chairman, Pres & CEO -
Amit Kumar,
Chairman of the Board, President, Chief Executive Officer -
Michael J. Catelani CPA, MBA,
Pres, COO, CFO & Corp. Sec. -
Michael J. Catelani,
COO, CFO & Corp. Sec. -
Michael Catelani,
Chief Financial Officer, Chief Operating Officer -
Lewis Titterton,
Lead Independent Director -
John Monahan,
Independent Director -
Emily Gottschalk,
Independent Director -
David Cavalier,
Independent Director -
Arnold Baskies,
Independent Director -
Thomas Schlumpberger,
Executive Vice President -
Dr. Pamela D. Garzone Ph.D.,
Chief Devel. Officer -
John Roop,
Sr. VP of Engineering